Questions
Ipamorelin: the questions people actually ask, answered straight.
Definitions, mechanism, risks, and the combination questions — each answer direct and cited where it makes a number claim.
What is ipamorelin?
Ipamorelin is a synthetic five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective ghrelin-receptor (GHS-R1a) agonist. In its founding characterization it released growth hormone potently in rat cells, rats, and swine — a swine ED50 of 2.3 nmol/kg — without raising ACTH or cortisol, making it the first selective growth hormone secretagogue [1]. It is not an approved drug.
What does ipamorelin do for you?
In the research, ipamorelin triggers a discrete pulse of growth hormone by selectively activating the ghrelin receptor, with minimal effect on cortisol or prolactin [1]. People in research-use communities most often report better sleep and faster recovery, but those are anecdotal. The one human outcome trial, for postoperative ileus, failed [3], so no proven human benefit has been established.
What is ipamorelin peptide?
Ipamorelin peptide is a wholly synthetic pentapeptide — five amino acids strung in the order Aib-His-D-2-Nal-D-Phe-Lys-NH2, with a molecular weight near 712 daltons. It mimics the body's ghrelin to activate the GHS-R1a receptor and release growth hormone selectively [1]. It was developed in the 1990s and is sold only as a research chemical, never approved as a medicine [3].
How does CJC-1295 ipamorelin work?
The pairing hits two complementary levers. CJC-1295 is a GHRH analog acting on the GHRH receptor; ipamorelin is a GHS-R1a (ghrelin-receptor) agonist acting through a separate calcium-driven pathway [1]. Because ghrelin-side agonists also suppress somatostatin, the GH brake, the two routes amplify each other in the underlying neuroendocrine literature [7]. No controlled trial has tested the combination itself [3].
Is ipamorelin selective for growth hormone?
Yes — that is its defining feature. In the 1998 founding study, ipamorelin released GH as potently as GHRP-6 but did not raise ACTH or cortisol above baseline, even at doses more than 200-fold above its GH threshold [1]. A swine study independently confirmed the selective GH-release profile [8]. It is described in the literature as the first selective growth hormone secretagogue [1].
What are the risks of ipamorelin?
The honest answer is that long-term human risk is uncharacterized. The only Phase 2 trial recorded adverse events in 87.5% of the ipamorelin arm versus 94.8% of placebo over up to 7 days, with no ipamorelin-specific signal in that brief window [3]. A 28-day study of a related ghrelin-receptor agonist found dose-dependent heart-muscle damage in rats — a class-level signal, not an ipamorelin finding [6]. No long-term safety database exists.
Does ipamorelin reduce belly fat?
There is no human trial showing ipamorelin reduces belly fat. In animals, it affects body composition: a 2024 ferret study found it blunted chemotherapy-driven weight loss by about 24% during the delayed phase [5], and an ipamorelin-derived oral analog drove body-weight gain in rats [11]. Community reports of a gradual leaner look are anecdotal and confounded by diet and training — not a clinical finding.
What are the downsides of ipamorelin?
Beyond reported side effects like facial flushing, more hunger, and mild puffiness, the substantive downside is the evidence gap: ipamorelin has no approved indication and its one Phase 2 trial failed its primary endpoint [3]. There is a class-level cardiac signal from a related agonist over 28 days [6], no long-term human data, and unregulated supply of unverified purity. The marketing far outpaces the proof.
Why is ipamorelin being discontinued?
Ipamorelin's clinical development effectively stopped because its only Phase 2 trial, for postoperative ileus, missed its primary endpoint — time to first tolerated meal was 25.3 hours versus 32.6 hours on placebo (p=0.15) [3] — and no Phase 3 followed. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list, tightening compounding-pharmacy access.
What does CJC-1295 and ipamorelin do?
Together they aim to raise growth hormone through two complementary pathways: CJC-1295 amplifies the GHRH signal, while ipamorelin adds a selective ghrelin-receptor signal that suppresses the GH brake somatostatin and stimulates GH release [7][1]. The neuroendocrine rationale is sound, but no controlled trial has tested the combination for sleep, recovery, body composition, or any other outcome [3].
Does ipamorelin increase IGF-1?
Not consistently in short studies. Ipamorelin releases growth hormone, which can drive the liver to make IGF-1 — but in the 15-day rat bone-growth study, total IGF-1 did not change even as bone growth increased, pointing to a partly local GH-pulse effect rather than a sustained IGF-1 rise [4]. Whether sustained human protocols would raise IGF-1 has not been characterized in controlled trials.
How much CJC-1295 ipamorelin should I take?
No published human study establishes a dose for the CJC-1295 plus ipamorelin combination, so there is no evidence-based answer and this digest does not provide one [3]. The controlled human ipamorelin record consists only of intravenous, clinic-administered protocols [2][3]. Community "stack" doses circulating online are anecdotal, rest on single-agent pharmacology, and have no controlled-trial basis [7].
Does CJC-1295 ipamorelin work?
The mechanism is genuine — pairing a GHRH analog with a GHS-R1a agonist hits two complementary GH-release levers that synergize in the neuroendocrine literature [7]. But "works" cannot be confirmed from combination data, because no trial has tested the pairing for any outcome [3]. Reported benefits like better sleep are anecdotal. The honest position: a sound rationale, no combination evidence.
How to reconstitute CJC-1295 ipamorelin 5mg?
As a general research-handling matter, ipamorelin is supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic water, then kept refrigerated because peptides degrade with heat and freeze-thaw. That is a handling observation, not a clinical preparation instruction, and no specific volume is endorsed here. No published human protocol exists for a CJC-1295 plus ipamorelin preparation [3].
How long does ipamorelin stay in your system?
In healthy human volunteers, ipamorelin showed a terminal half-life of approximately 2 hours by the intravenous route, with the growth-hormone pulse peaking about 40 minutes after dosing [2]. As a rough rule, a drug is largely cleared after several half-lives, so ipamorelin's measurable presence is short-lived — though anti-doping laboratories can still detect growth hormone secretagogues by dedicated urine methods.
Does ipamorelin make you hungry?
Some users report increased hunger in the hours after injecting, which fits the mechanism — ipamorelin activates the ghrelin (hunger) receptor [1]. Community accounts generally call it milder than the hunger from older peptides like GHRP-6, but real enough to matter for anyone watching intake. This is an occasionally-reported, anecdotal effect, not a measured outcome from a human trial.
Will I gain weight on ipamorelin?
No human trial answers this. In animals, ipamorelin-class compounds alter body composition — an ipamorelin-derived oral analog produced significant body-weight gain in rats over 14 days [11], and ipamorelin blunted weight loss in a ferret cachexia model [5]. Any human weight change would be confounded by appetite effects, diet, and training, and is not established by controlled data. Reported effects are anecdotal.
Does ipamorelin increase appetite?
It can, by mechanism: ipamorelin activates GHS-R1a, the ghrelin receptor that governs appetite [1], and increased hunger is an occasionally-reported community effect. A 2026 critical review of peptide use in sport notes the GH-axis risks of this class in uncontrolled use [9]. Community accounts describe the appetite bump as milder than with GHRP-6 — but it is an anecdotal observation, not a measured trial endpoint.
What does ipamorelin peptide do?
Ipamorelin peptide selectively activates the ghrelin receptor (GHS-R1a) on pituitary cells, triggering a discrete growth-hormone pulse with minimal cortisol or prolactin [1]. Downstream, growth hormone can raise IGF-1, though not consistently in short studies [4]. In humans, the one outcome trial it was tested in — for bowel recovery after surgery — failed [3], so its proven human effects are limited to the pharmacology, not a therapeutic result.
How long does it take for ipamorelin to work?
Pharmacologically, fast: the growth-hormone pulse peaks about 40 minutes after an intravenous dose in humans, with a roughly 2-hour half-life [2]. That is the GH response, not a wellness outcome. Community reports of sleep improvements often describe the first one to two weeks, but those are anecdotal and unverified — no controlled human trial has measured a time-to-effect for any wellness endpoint.
Does ipamorelin cause water retention?
Mild water retention and puffiness — in fingers, ankles, or face during the first few weeks — is an occasionally-reported community effect, generally described as milder than with older GH-releasing peptides and tending to ease with continued use. It is biologically plausible because growth-hormone excess is linked to sodium and water retention, but it is an anecdotal report here, not a measured finding from a controlled ipamorelin trial [3].
Where to inject CJC-1295 ipamorelin?
This digest does not give injection instructions. For context only: in the research literature the dominant route for this peptide class is subcutaneous, and the controlled human ipamorelin studies used the intravenous route in a clinic setting [2][3]. There is no published human protocol for self-administering a CJC-1295 plus ipamorelin combination [3], and nothing here should be read as guidance on how or where to inject anything.